Hao-Yuan Chuang Sells 367 Shares of Belite Bio (NASDAQ:BLTE) Stock

Key Points

• CFO Hao-Yuan Chuang sold 367 Belite Bio shares at an average price of $180.35, generating $66,188.45. He retained 93,433 shares after the transaction, representing a 0.39% reduction in ownership.
• Belite Bio shares opened at $166.26 after falling 7.1%, while the clinical-stage biotechnology company continues to report losses. Analysts expect a full-year loss of $3.17 per share.
• Despite the insider sale and volatility, sentiment remains broadly positive: the FDA granted priority review to tinlarebant for Stargardt disease, and analysts maintain a “Moderate Buy” consensus with an average price target of $204.40.

Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE - Get Free Report) CFO Hao-Yuan Chuang sold 367 shares of Belite Bio stock in a transaction that occurred on Wednesday, August 12th. The shares were sold at an average price of $180.35, for a total transaction of $66,188.45. Following the completion of the sale, the chief financial officer owned 93,433 shares of the company's stock, valued at approximately $16,850,641.55. The trade was a 0.39% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Belite Bio Stock Down 7.1%

BLTE opened at $166.26 on Friday. The stock has a market capitalization of $6.66 billion, a price-to-earnings ratio of -65.72 and a beta of -1.22. Belite Bio, Inc. Sponsored ADR has a twelve month low of $60.00 and a twelve month high of $200.00. The company has a 50-day simple moving average of $152.11 and a 200 day simple moving average of $159.84.

Belite Bio (NASDAQ:BLTE - Get Free Report) last issued its earnings results on Friday, May 15th. The company reported ($0.34) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.26. Sell-side analysts anticipate that Belite Bio, Inc. Sponsored ADR will post -3.17 EPS for the current fiscal year.

Institutional Trading of Belite Bio

Hedge funds and other institutional investors have recently bought and sold shares of the business. Caitong International Asset Management Co. Ltd grew its holdings in Belite Bio by 28,200.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 283 shares of the company's stock worth $45,000 after buying an additional 282 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in Belite Bio during the 4th quarter valued at $103,000. Persistent Asset Partners Ltd bought a new position in Belite Bio during the 4th quarter valued at $108,000. Bank of America Corp DE boosted its holdings in Belite Bio by 28.1% during the 3rd quarter. Bank of America Corp DE now owns 1,171 shares of the company's stock worth $87,000 after acquiring an additional 257 shares during the last quarter. Finally, Independent Advisor Alliance purchased a new position in Belite Bio during the 4th quarter worth $211,000. Institutional investors own 0.53% of the company's stock.

Trending Headlines about Belite Bio

Here are the key news stories impacting Belite Bio this week:

• Positive Sentiment: The FDA granted priority review to Belite Bio’s tinlarebant New Drug Application for Stargardt disease. The accelerated review sets an expected decision date in February 2027 and follows positive Phase 3 data, potentially shortening the path to commercialization for the company’s lead program. BLTE Stock Rises as FDA Grants Priority Review to Tinlarebant NDA
• Positive Sentiment: HC Wainwright raised its price target to $214 from $200 and maintained a Buy rating, signaling continued analyst confidence in tinlarebant’s commercial potential. Belite Bio Price Target Increase
• Positive Sentiment: Second-quarter results exceeded expectations: Belite Bio reported a loss of $0.54 per share versus the consensus estimate of a $0.73 loss. The earnings beat may support sentiment, while management’s corporate update and earnings call provided additional detail on the company’s development programs. Belite Bio Second Quarter 2026 Results
• Neutral Sentiment: Belite Bio remains a clinical-stage biotechnology company, so its valuation and stock performance remain highly dependent on regulatory decisions, clinical execution and the future launch of tinlarebant. Belite Bio Q2 2026 Earnings Call Transcript
• Negative Sentiment: The company continues to report net losses, and analysts expect a full-year loss. With shares trading near their yearly high and at a loss-based price-to-earnings valuation, investors may be taking profits despite the positive FDA and earnings developments.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on BLTE shares. Truist Financial set a $217.00 price objective on Belite Bio in a research report on Friday, May 22nd. HC Wainwright raised their price target on shares of Belite Bio from $200.00 to $214.00 and gave the stock a "buy" rating in a report on Wednesday. Cantor Fitzgerald restated an "overweight" rating on shares of Belite Bio in a research report on Wednesday. Benchmark reaffirmed a "buy" rating on shares of Belite Bio in a research note on Friday, May 22nd. Finally, Mizuho decreased their price objective on shares of Belite Bio from $223.00 to $215.00 and set an "outperform" rating for the company in a research report on Tuesday, May 26th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Belite Bio currently has an average rating of "Moderate Buy" and an average target price of $204.40.

Belite Bio Company Profile

Belite Bio, Inc NASDAQ: BLTE is a clinical-stage biotechnology company focused on discovering and developing small molecule therapeutics for metabolic and inflammatory diseases. Leveraging a proprietary drug-discovery platform, the company aims to address conditions such as nonalcoholic steatohepatitis (NASH) and obesity by targeting pathways involved in fibrosis, inflammation and metabolic regulation.

Belite Bio’s pipeline includes multiple candidates in preclinical and early clinical development stages.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source